Pediatric Cytomegalovirus Infection Treatment & Management: Medical Care, Surgical Care, Consultations (original) (raw)

Medical Care

Medical care of cytomegalovirus (CMV) consists of good nutritional support, vigorous supportive care for end-organ syndromes (particularly pneumonia in immunocompromised patients), and specific antiviral therapy in select circumstances.

eMedicine Logo

Surgical Care

Some children with congenital cytomegalovirus (CMV) infection require orthopedic interventions (eg, for cerebral palsy) and gastrostomy placement for enteral nutrition.

eMedicine Logo

Consultations

Depending on the patient and associated risk factors, cytomegalovirus (CMV) disease is encountered by obstetricians, pediatricians, infectious disease specialists, oncologists, critical care physicians, and other healthcare providers. Appropriate consultations with surgeons, developmental specialists, pathologists, otolaryngologists, ophthalmologists, neurologists, and gastroenterologists may be necessary.

eMedicine Logo

Prevention

Ultimately, control of cytomegalovirus (CMV) infection, particularly the devastating sequelae of congenital cytomegalic inclusion disease (CID), depends on immunization.

The major target population for a CMV vaccine is women of childbearing age. Although immunization is unlikely to prevent all congenital infection, the hope is that immunization can have a significant and major impact on the prevalence of CID.

A vaccine may also be useful in controlling CMV disease in organ transplant recipients. A live-attenuated vaccine, the Towne vaccine, showed promise for prevention of CMV disease in studies involving renal transplant recipients reported in the 1980s. However, the Towne strain of CMV is poorly immunogenic, probably because it has been overly attenuated during the process of tissue culture passage.

Newer technologies using recombinant chimeric viruses that represent genetic hybrids between Towne virus and a low-passage clinical isolate, the Toledo strain, are currently under investigation as the next generation of live-virus CMV vaccines.

Subunit vaccine approaches are also being explored. These use molecularly cloned, eucaryotically expressed forms of the major immunogenic CMV envelope protein, gB, and are being actively investigated in clinical trials.

A phase II, placebo-controlled, randomized, double-blind trial by Pass et al evaluated a recombinant CMV vaccine (envelope glycoprotein B with MF59 adjuvant). Three doses of the CMV vaccine or placebo were administered at 0, 1, and 6 months to 464 CMV-seronegative women within 1 year after they had given birth. After a minimum of 1 year of follow-up, 49 confirmed infections were noted, 18 in the vaccine group and 31 in the placebo group. One congenital infection among infants of the study subjects occurred in the vaccine group, and 3 infections occurred in the placebo group. Ongoing research continues to evaluate the potential for a CMV vaccine to decrease maternal and congenital CMV infection. [50] Another study of this vaccine in solid organ transplant patients at risk for CMV infection and disease also indicated efficacy in seronegative transplant recipients. [51]

A prospective, multicenter birth-cohort study was conducted to estimate the risk of postnatal CMV transmission from transfusion of CMV-seronegative and leukoreduced blood and also maternal breast milk. The study concluded that transfusion of CMV-seronegative and leukoreduced blood products effectively prevents transmission of CMV to very low-birth-weight (VLBW) infants. The study further concluded that among infants whose care is managed with the transfusion of CMV-seronegative and leukoreduced blood, maternal breast milk is the primary source of postnatal CMV infection. [52]

A vectored vaccine approach in a genetically engineered poxvirus vector, canarypox, is also under evaluation. In addition to gB, this approach targets the major cytotoxic T-cell (CTL) target, the UL83 gene product.

DNA vaccines have also shown promise for prevention of CMV infection, and they have demonstrated some degree of efficacy in the transplantation setting. [53]

CMV has been demonstrated to enter epithelial and endothelial cells by different pathways than those used for entry into fibroblasts, and a complex of CMV proteins (ie, gH/gL/UL128/130/131 complex) is essential for this process. This discovery has provided a new potential target for vaccines. [33]

Until the goal of a CMV vaccine is realized, educating women of childbearing age about the risks of CMV and about how to avoid disease transmission are the only control strategies available. A survey of 726 women aged 18-44 years in Minnesota found that only 20% of the women were aware of congenital CMV infection. [54]

Seronegative women who regularly come in close contact with large numbers of young children, particularly in daycare environments, may be at particularly high risk.

Acquisition of primary cytomegalovirus (CMV) infection during pregnancy is a major concern. Women at high risk include those with extensive daycare contact, particularly individuals who work in large daycare facilities in which repeated exposures are common. [55]

Behaviors known to be associated with transmission of infection, particularly kissing and sharing eating utensils, can be avoided, and careful handwashing after diaper changes should be stressed.

eMedicine Logo

  1. Schleiss MR. Persistent and recurring viral infections: the human herpesviruses. Curr Probl Pediatr Adolesc Health Care. 2009 Jan. 39(1):7-23. [QxMD MEDLINE Link].
  2. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. J Intern Med. 2006 Mar. 259(3):219-46. [QxMD MEDLINE Link].
  3. Goodpasture EQ, Talbot FB. Concerning the nature of "protozoan-like" cells in certain lesions of infancy. Am J Dis Child. 1921. 21:415.
  4. Weller TH, Hanshaw JB. Virologic and clinical observations on cytomegalic inclusion disease. N Engl J Med. 1962 Jun 14. 266:1233-44. [QxMD MEDLINE Link].
  5. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med. 1971 Jul 22. 285(4):203-14. [QxMD MEDLINE Link].
  6. Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther. 2004 Jun. 2(3):389-403. [QxMD MEDLINE Link].
  7. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010 Nov. 9(11):1303-14. [QxMD MEDLINE Link].
  8. Schleiss MR. Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infect Disord Drug Targets. 2011 Oct. 11(5):449-65. [QxMD MEDLINE Link].
  9. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul. 143(1):16-25. [QxMD MEDLINE Link].
  10. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A. 2005 Dec 13. 102(50):18153-8. [QxMD MEDLINE Link].
  11. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol. 2006 Jan. 80(2):710-22. [QxMD MEDLINE Link].
  12. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005 Sep 5. 202(5):673-85. [QxMD MEDLINE Link].
  13. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995 Oct 19. 333(16):1038-44. [QxMD MEDLINE Link].
  14. Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation. Virol J. 2009 Jan 9. 6:4. [QxMD MEDLINE Link]. [Full Text].
  15. Schleiss MR. Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines. J Clin Invest. 2010 Dec. 120(12):4192-7. [QxMD MEDLINE Link].
  16. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis. 1990 Sep-Oct. 12 Suppl 7:S701-10. [QxMD MEDLINE Link].
  17. Pesch MH, Schleiss MR. Emerging concepts in congenital cytomegalovirus. Pediatrics. 2022 Aug 1. 150 (2):[QxMD MEDLINE Link].
  18. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007 Jul-Aug. 17(4):253-76. [QxMD MEDLINE Link].
  19. Dar L, Pati SK, Patro AR, et al. Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J. 2008 Sep. 27(9):841-3. [QxMD MEDLINE Link].
  20. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010 Apr 14. 303(14):1375-82. [QxMD MEDLINE Link].
  21. Kabani N, Ross SA. Congenital cytomegalovirus infection. J Infect Dis. 2020 Mar 5. 221 (Suppl 1):S9-S14. [QxMD MEDLINE Link]. [Full Text].
  22. Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020 Sep. 223 (3):330-49. [QxMD MEDLINE Link].
  23. Dworsky M, Yow M, Stagno S, Pass RF, Alford C. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics. 1983 Sep. 72(3):295-9. [QxMD MEDLINE Link].
  24. Hamele M, Flanagan R, Loomis CA, Stevens T, Fairchok MP. Severe morbidity and mortality with breast milk associated cytomegalovirus infection. Pediatr Infect Dis J. 2010 Jan. 29(1):84-6. [QxMD MEDLINE Link].
  25. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010 Jun 1. 50(11):1439-47. [QxMD MEDLINE Link].
  26. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010 Jul. 20(4):202-13. [QxMD MEDLINE Link].
  27. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995 Jan. 171(1):26-32. [QxMD MEDLINE Link].
  28. Fowler KB, Pass RF. Risk factors for congenital cytomegalovirus infection in the offspring of young women: exposure to young children and recent onset of sexual activity. Pediatrics. 2006 Aug. 118(2):e286-92. [QxMD MEDLINE Link].
  29. [Guideline] Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002 Jun 14. 51:1-52. [QxMD MEDLINE Link].
  30. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007 Jul 2. 7:71. [QxMD MEDLINE Link]. [Full Text].
  31. Gunkel J, de Vries LS, Jongmans M, Koopman-Esseboom C, van Haastert IC, Eijsermans MCJ, et al. Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection. Pediatrics. 2018 Feb. 141 (2):[QxMD MEDLINE Link].
  32. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001 May 3. 344(18):1366-71. [QxMD MEDLINE Link].
  33. Schleiss MR. Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface. Expert Opin Ther Pat. 2010 Apr. 20(4):597-602. [QxMD MEDLINE Link].
  34. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007 Sep-Oct. 17(5):355-63. [QxMD MEDLINE Link].
  35. Bale JF, Miner L, Petheram SJ. Congenital Cytomegalovirus Infection. Curr Treat Options Neurol. 2002 May. 4(3):225-230. [QxMD MEDLINE Link].
  36. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009 Jan. 22(1):99-126, Table of Contents. [QxMD MEDLINE Link].
  37. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics. 1992 Dec. 90(6):862-6. [QxMD MEDLINE Link].
  38. Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr. 1997 Apr. 130(4):624-30. [QxMD MEDLINE Link].
  39. Foulon I, Naessens A, Foulon W, Casteels A, Gordts F. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr. 2008 Jul. 153(1):84-8. [QxMD MEDLINE Link].
  40. Torpy JM, Burke AE, Glass RM. JAMA patient page. Cytomegalovirus. JAMA. 2010 Apr 14. 303(14):1440. [QxMD MEDLINE Link].
  41. Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health. 2005. 5:70. [QxMD MEDLINE Link].
  42. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr. 1999 Jul. 135(1):60-4. [QxMD MEDLINE Link].
  43. Horwitz CA, Henle W, Henle G, et al. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore). 1986 Mar. 65(2):124-34. [QxMD MEDLINE Link].
  44. Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis. 2001 Aug 1. 33(3):370-4. [QxMD MEDLINE Link].
  45. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. 1985 Feb. 21(2):217-21. [QxMD MEDLINE Link]. [Full Text].
  46. Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis. 1988 Dec. 158(6):1177-84. [QxMD MEDLINE Link].
  47. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011 Feb. 25(1):151-69. [QxMD MEDLINE Link].
  48. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008 Aug 21. 14(31):4849-60. [QxMD MEDLINE Link].
  49. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010 Apr 14. 303(14):1375-82. [QxMD MEDLINE Link].
  50. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19. 360(12):1191-9. [QxMD MEDLINE Link]. [Full Text].
  51. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011 Apr 9. 377(9773):1256-63. [QxMD MEDLINE Link].
  52. Josephson CD, Caliendo AM, Easley KA, Knezevic A, Shenvi N, Hinkes MT, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr. 2014 Nov. 168(11):1054-62. [QxMD MEDLINE Link].
  53. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr. 12(4):290-9. [QxMD MEDLINE Link].
  54. Tastad KJ, Schleiss MR, Lammert SM, Basta NE. Awareness of congenital cytomegalovirus and acceptance of maternal and newborn screening. PLoS One. 2019. 14 (8):e0221725. [QxMD MEDLINE Link]. [Full Text].
  55. Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med. 1989 Nov 9. 321(19):1290-6. [QxMD MEDLINE Link].
  56. Schleiss M, Stanberry L. Herpesvirus infections of the neonatal CNS: Similarities and differences between HSV and CMV. Herpes. 1997. 4:74.
  57. Schleiss MR. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J Pediatr. 2007 Dec. 151(6):564-70. [QxMD MEDLINE Link].
  58. Tabata T, McDonagh S, Kawakatsu H, Pereira L. Cytotrophoblasts infected with a pathogenic human cytomegalovirus strain dysregulate cell-matrix and cell-cell adhesion molecules: a quantitative analysis. Placenta. 2007 May-Jun. 28(5-6):527-37. [QxMD MEDLINE Link].
  59. Zhang C, Buchanan H, Andrews W, Evans A, Pass RF. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol. 2006 Mar. 35(3):338-42. [QxMD MEDLINE Link].

Author

Mark R Schleiss, MD Minnesota American Legion and Auxiliary Heart Research Foundation Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.